24 search results for: disease progression

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Rhinology
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
expert video

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

View more
.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

What Are the Key Inflammatory Processes in Patients with COPD?
Pulmonology
What Are the Key Inflammatory Processes in Patients with COPD?
expert video

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

View more
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Type 2 Inflammation
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
expert video

Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

View more
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
On Demand
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Drs. Elmariah, Kim, and Metz explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

.
Congress
1
December
2023
Congress
Global ADVENT FORUM 2023, Dermatology Section | Madrid

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
ERS 2024 | Understanding the Complex Pathophysiology of COPD
expert video

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

View more
Risk of Mortality and Infections in Bullous Pemphigoid
Dermatology
Risk of Mortality and Infections in Bullous Pemphigoid
expert video

Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis

View more
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Congress
11
March
2024
Congress
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Coverpage
Congress
8
March
2024
Congress
ADVENT at San Diego, 2024

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
Dermatology
Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
expert video

Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

View more